PI 3-kinase fusion mutants and uses thereof

Details PI 3-kinase fusion mutants and uses thereof PI 3-kinase fusion mutants and uses thereof

1997-04-02

2003-09-02

Guzo, David (Department: 1636)

Multicellular living organisms and unmodified parts thereof and

Method of using a transgenic nonhuman animal in an in vivo...

C800S013000, C536S023100, C536S023200, C536S023400, C435S320100, C435S455000

Reexamination Certificate

active

06613956

ABSTRACT:

GENERAL DESCRIPTION
1. Field of the Invention
This invention provides polynucleotide constructs encoding constitutively active membrane-targeted PI 3-kinase mutants, methods for making polynucleotide constructs, an in vivo method for screening for inhibitors of PI 3-kinase using the constructs, use of the polynucleotide constructs to prevent cell death, or to restore insulin responsiveness in type II diabetes, use of the polynucleotide constructs to express PI 3-kinase mutants that generate 3′ phosphorylated inositol phospholipids, and use of these phospholipids to prevent cell death.
2. Background of the Invention
Phosphotidylinositol (PI) 3-kinase, both a phospholipid kinase, and a protein serine/threonine kinase, is implicated in certain oncogenic or mitogenic responses. See Carpenter et al.,
Mol. Cell. Biol
. 13:1657-1665 (1993), Cantley et al.,
Cell
64:281-302 (1991), Escobedo and Williams,
Nature
335:85-87 (1988), and Fantl et al,
Cell
69: 413423 (1992). It is an intracellular heterodimer consisting of an 85-kDa regulatory subunit (p85), and a 110-kDa catalytic subunit (p110) that is stimulated by growth factors. See Whitman et al.,
Nature
332:644-646 (1988). The p85 subunit contains several domains and links the catalytic subunit to activated growth factor receptors. The cDNA for the p110 subunit has recently been cloned and expressed in insect and mammalian systems as described in Hiles et al.,
Cell
70:419-429 (1992). The general structure and function of PI 3-kinase, including analysis of the structure and function of its subunits p85 and p110, are described in Klippel et al.,
Mol. Cell. Biol
. 13:5560-5566 (1993), and in Klippel et al.,
Mol. Cell. Biol
. 14:2675-2685 (1994).
The p85 subunit of PI 3-kinase has several domains, including a 200 amino acid region of p85 located between the two SH2 domains. This domain, called the inter-SH2 or iSH2 domain, has been found sufficient to promote interaction with p110 in vivo with activity comparable to that of full-length p85. See Klippel et al.,
Mol. Cell. Biol
. 13:5560-5566 (1993). Additionally, a complex between a 102 amino acid segment of p85 and the p110 subunit has been found to be catalytically active, as described in and Klippel et al.,
Mol. Cell. Biol
. 14:2675-2685 (1994).
Previously, studies to elucidate the of PI 3-kinase activation have been conducted by constructing receptor mutants to alter the signal transduction of PI 3-kinase, or by constructing mutant oncogenes to study a PI 3-kinase inducible oncogenic response. It would be advantageous to study effects of PI 3-kinase activation directly, without growth factor activation, so as to identify the role of PI 3-kinase in oncogenesis, mitogenesis, and other tyrosine kinase and PI related functions. Methods and compositions derived from such knowledge and use of PI 3-kinase to control oncogenesis or mitogenesis, would be advantageous in the treatment of cancer. In addition, it would be advantageous to develop methods and compositions for such applications as preventing cell death or treating type II diabetes.
SUMMARY OF THE INVENTION
In one aspect, the invention provides polynucleotide sequences comprising the p110 subunit of PI 3-kinase polynucleotide attached to a cell membrane targeting sequence. More specifically, the invention provides a polynucleotide sequence comprising a first nucleotide sequence encoding the p110 subunit of PI 3-kinase protein, or a derivative or mutant of this sequence having a single or multiple nucleotide substitution, deletion or addition, this derivative or mutant having p110 catalytic activity, and a second nucleotide sequence encoding a cell membrane targeting sequence, this second nucleotide sequence being attached to the first nucleotide sequence at the latter's 5′ or 3′ end. Further, the polynucleotide sequence of the invention can be structured so that the first nucleotide sequence also includes a nucleotide sequence encoding the p85 subunit of PI 3-kinase or a fragment of the p85 subunit, for example the iSH2 domain of the p85 subunit, capable of binding the p110 subunit. The cell membrane targeting sequence is a nucleotide sequence encoding a myristoylation, or a palmitoylation and farnesylation amino acid sequence.
Other aspects of the invention include methods of screening for inhibitors of PI 3-kinase, methods of making 3′ phosphorylated inositol phospholipids, and the 3′ phosphorylated inositol phospholipid produced thereby, and methods for activating enzyme effectors of PI 3-kinase having a pleckstrin homology domain.
Therapeutic aspects of the invention include methods of reducing cell death due to trauma, by administering to the cell a viral or non-viral vector including a polynucleotide sequence of the invention, or by administering a 3′ phosphorylated inositol phospholipid to the cell. Another aspect of the invention is a method of promoting activation of an insulin signaling pathway by contacting a cell characterized by insulin resistance with a vector having a polynucleotide sequence of the invention.


REFERENCES:
patent: PCT/US97/05573 (1997-04-01), None
P Rodriguez-Viciana et al (1994) Nature; 370: 527-532.*
Whitman et al., “Type I Phosphatidylinositol Kinase Makes a Novel Inositol Phospholipid, Phosphatidylinositol-3-Phosphate”Nature 332:644-646, Apr., 1988.
Varticovski et al., “Activation of Phosphatidylinositol 3-Kinase in Cells Expressing abl Oncogene Variants”Molecular and Cellular Biology 11(2):1107-1113, Feb., 1991.
Aronheim et al., “Membrane Targeting of the Nucleotide Exchange Factor Sos is Sufficient for Activating the Ras Signalling Pathway”Cell 78:949-961, Sep., 1994.
Klippel et al., “Membrane Localization of Phosphatidylinositol 3-Kinase is Sufficient to Activate Multiple Signal-Transducing Kinase Pathways”Molecular and Cellular Biology 16(8):4117-4127, Aug., 1996.
Didichenko et al., “Constitutive Activation of Protein Kinase B and Phosphorylation of p47phoxby a Membrane-Targeted Phosphoinositide 3-Kinase”Current Biology 6(10):1271-1278, Oct., 1996.
Reif et al., “Phosphatidylinositol 3-Kinase Signals Activate a Selective Subset of Rac/Rho-dependent Effector Pathways”Current Biology 6(11):1445-1455, Nov., 1996.
Klippel et al., “A Region of the 85-Kilodalton (kDa) Subunit of Phosphatidylinositol 3-Kinase Binds the 110-kDa Catalytic Subunit In Vivo”Molecular and Cellular Biology 13(9):5560-5566, Sep., 1993.
Klippel et al., “The Interaction of Small Domains Between the Subunits of Phosphatidylinositol 3-Kinase Determines Enzyme Activity”Molecular and Cellular Biology 14(4):2675-2685, Apr., 1994.
Hu et al., “Ras-Dependent Induction of Cellular Responses by Constitutively Active Phosphatidylinositol-3 Kinase”Science 268:100-102, Apr., 1995.
Kapeller and Cantley, “Phosphatidylinositol 3-Kinase”BioEssays 16(8):565-576, 1994.
Stephens et al., “Agonist-Stimulated Synthesis of Phosphatidylinositol (3,4,5)—Trisphosphate: a New Intracellular Signalling System”Biochimica et Biophysica Acta. 1179:27-75, 1993.
Hiles et al., “Phosphatidylinositol 3-Kinase: Structure and Expression of the 110 kd Catalytic Subunit”Cell 70:419-429, Aug., 1992.
Escobedo et al., “cDNA Cloning of a Novel 85 kd Protein that has SH2 Domains and Regulates Binding of P13-Kinase to the PDGF &bgr;-Receptor”Cell 65:75-82, 1991.
Buss et al., “Activation of the Cellular Proto-Oncogene Product p21 Ras by Addition of a Myristylation Signal”Science 243:1600-1603, 1989.
Kaplan et al., “Phosphatidylinositol Metabolism and Polyoma-Mediated Transformation”Proc. Natl. Acad. Sci. USA 83:3624-3628, Jun., 1986.
Schultz et al., “Amino Terminal Myristylation of the Protein Kinase p60src, a Retroviral Transforming Protein”Science 227:427-429, 1985.
Deichaite et al., “In Vitro Synthesis of pp60v-src.: Myristylation in a Cell-Free System”Mol. Cell Biol. 8(10):4295-4301, Oct., 1988.
Cadwallader et al., “N-Terminally Myristoylated Ras Proteins Require Palmitoylation or a Polybasic Domain for Plasma Membrane Localization”Mol. Cell Biol. 14(7):4722-4730, Jul., 1994.
Hay et al., “Expression of Baculovirus P35

Affiliated with

Also associated with

Rating

PI 3-kinase fusion mutants and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PI 3-kinase fusion mutants and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PI 3-kinase fusion mutants and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3059528